September 27, 2017
Novo Nordisk’s diabetes drug in China
China Food and Drug Administration (CFDA) has approved Novo Nordisk’s Tresiba (insulin degludec) for the treatment of diabetes in China.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Novo Nordisk
August 25, 2017
FDA OK’s Novo Nordisk’s diabetes drug
The U.S. Food and Drug Administration (FDA) has approved a new indication for Novo Nordisk’s Victoza (liraglutide) to reduce the risk of major adverse cardiovascular (CV) events in adults with type 2 diabetes and established CV disease.
June 23, 2017
LEADER trial data included in Novo Nordisks Saxenda in Europe
Novo Nordisk got the right from the European Medicines Agency’s committee (EMA) to include data from the LEADER trial to Saxenda to the results from the trial showed the long-term effects of Victoza for type 2 diabetes and established cardiovascular disease patients.
June 7, 2017
Lyfebulb and Novo Nordisk team up again to advance entrepreneur innovation in diabetes management
Lyfebulb and Novo Nordisk have join again to support international patient entrepreneurs who develop innovative ideas and concepts aimed to positively empower and impact the lives of people living with type 1 or type 2 diabetes – and ultimately our societies.
June 6, 2017
Novo Nordisk to sell its haemophilia B drug in EU
European Commission has granted marketing authorisation for Novo Nordisk’s Refixia for the treatment of adolescents and adults with haemophilia B.
June 1, 2017
BLA approval for Novo Nordisk’s Rebinyn for heamophilia B
Rebinyn got US FDA’s approval and is hoped to become an important tool for physicians to help patients manage their bleeds.
May 23, 2017
Novo Nordisk submits application in the US for label addition for its diabetes drug
Novo Nordisk has submitted a supplemental application to the US Food and Drug Administration (FDA) for including data in the label for Tresiba (insulin degludec) from the DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial conducted to confirm the cardiovascular safety of Tresiba compared to insulin glargine U100 when added to standard of care, in people with type 2 diabetes.
May 3, 2017
Novo Nordisk reports 10% profit increase for Q1 2017
Novo Nordisk has reported profit of €1.4 billion for the first quarter of 2017, which is increase of 10%.
April 3, 2017
Once-weekly semaglutide lowers blood glucose and weight with type 2 diabetes patients
Novo Nordisk said Monday that once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment.
March 27, 2017
Novo Nordisk’s new fast-acting mealtime insulin to sell in Canada
Novo Nordisk’s new, fast-acting mealtime insulin for the treatment of diabetes in adults, Fiasp has been launched in Canada, following the recent marketing authorisation from Health Canada on 6 January 2017.